| Primary |
| Haemorrhage |
21.5% |
| Prophylaxis |
11.6% |
| Traumatic Haemorrhage |
7.8% |
| Hypertension |
6.4% |
| Cerebral Haemorrhage |
5.6% |
| Drug Use For Unknown Indication |
5.5% |
| Ill-defined Disorder |
5.5% |
| Sedation |
5.5% |
| Acquired Haemophilia |
5.3% |
| Post Procedural Haemorrhage |
3.8% |
| Shock Haemorrhagic |
2.8% |
| Product Used For Unknown Indication |
2.6% |
| Antibiotic Prophylaxis |
2.3% |
| Haemophilia A With Anti Factor Viii |
2.2% |
| Pain |
2.2% |
| Pyrexia |
2.1% |
| Prophylaxis Against Gastrointestinal Ulcer |
2.0% |
| Analgesia |
1.9% |
| Factor Vii Deficiency |
1.8% |
| Hypotension |
1.8% |
|
| Death |
15.9% |
| Drug Ineffective |
8.9% |
| Multi-organ Failure |
8.1% |
| Thrombosis |
7.5% |
| Sepsis |
6.6% |
| Shock Haemorrhagic |
5.8% |
| Haemorrhage |
5.5% |
| Cerebral Infarction |
5.0% |
| Pulmonary Embolism |
4.3% |
| Myocardial Infarction |
4.2% |
| Cerebrovascular Accident |
3.7% |
| Intestinal Infarction |
3.7% |
| Deep Vein Thrombosis |
3.4% |
| Therapeutic Response Decreased |
3.0% |
| Disseminated Intravascular Coagulation |
2.8% |
| Portal Vein Thrombosis |
2.5% |
| Renal Failure |
2.5% |
| Cardiac Arrest |
2.4% |
| Concomitant Disease Progression |
2.1% |
| Respiratory Failure |
2.1% |
|
| Secondary |
| Ill-defined Disorder |
30.7% |
| Haemorrhage |
11.3% |
| Acquired Haemophilia |
7.8% |
| Product Used For Unknown Indication |
7.0% |
| Haemorrhage Intracranial |
5.3% |
| Shock Haemorrhagic |
5.3% |
| Drug Use For Unknown Indication |
4.0% |
| Factor Viii Deficiency |
3.9% |
| Factor Viii Inhibition |
2.8% |
| Prophylaxis |
2.5% |
| Hypertension |
2.5% |
| Haemophilia A With Anti Factor Viii |
2.4% |
| Hypophagia |
2.4% |
| Depression |
2.0% |
| Haemostasis |
2.0% |
| Diabetes Mellitus |
1.9% |
| Factor Vii Deficiency |
1.8% |
| Coagulopathy |
1.6% |
| Congenital Thrombocyte Disorder |
1.4% |
| Gastric Ulcer |
1.4% |
|
| Thrombosis |
11.1% |
| Multi-organ Failure |
10.8% |
| Haemorrhage |
8.2% |
| Therapeutic Response Decreased |
7.2% |
| Death |
6.2% |
| Drug Ineffective |
6.2% |
| Jugular Vein Thrombosis |
6.2% |
| Shock Haemorrhagic |
5.4% |
| Cardiac Arrest |
4.6% |
| Pain |
4.1% |
| Portal Vein Thrombosis |
3.9% |
| Subarachnoid Haemorrhage |
3.6% |
| Deep Vein Thrombosis |
3.3% |
| Renal Failure Acute |
3.3% |
| Sudden Death |
3.1% |
| Cerebral Infarction |
2.8% |
| Pneumonia |
2.8% |
| Peripheral Ischaemia |
2.6% |
| Candida Sepsis |
2.3% |
| Septic Shock |
2.3% |
|
| Concomitant |
| Drug Use For Unknown Indication |
16.6% |
| Product Used For Unknown Indication |
14.5% |
| Factor Viii Deficiency |
12.0% |
| Hiv Infection |
7.8% |
| Haemorrhage |
6.3% |
| Factor Viii Inhibition |
5.3% |
| Haemarthrosis |
5.3% |
| Haemostasis |
4.6% |
| Acquired Haemophilia |
3.8% |
| Muscle Haemorrhage |
3.8% |
| Immunosuppression |
2.9% |
| Allogenic Bone Marrow Transplantation Therapy |
2.5% |
| Postpartum Haemorrhage |
2.5% |
| Haemophilia |
2.1% |
| Prophylaxis |
2.1% |
| Hepatitis C |
1.9% |
| Sedative Therapy |
1.9% |
| Multiple Sclerosis |
1.5% |
| Acquired Immunodeficiency Syndrome |
1.3% |
| Hypertension |
1.3% |
|
| Urticaria |
20.2% |
| Factor Viii Inhibition |
18.0% |
| Drug Ineffective |
5.6% |
| Device Related Infection |
4.5% |
| Disseminated Intravascular Coagulation |
4.5% |
| Haemorrhage |
4.5% |
| Platelet Count Decreased |
4.5% |
| Sepsis |
4.5% |
| Haemorrhagic Anaemia |
3.4% |
| Iridocyclitis |
3.4% |
| Jaundice |
3.4% |
| Osteonecrosis |
3.4% |
| Transmission Of An Infectious Agent Via A Medicinal Product |
3.4% |
| Vomiting |
3.4% |
| Acute Respiratory Distress Syndrome |
2.2% |
| Brain Neoplasm |
2.2% |
| Death |
2.2% |
| Haemorrhage Intracranial |
2.2% |
| Haemorrhagic Diathesis |
2.2% |
| Hypotension |
2.2% |
|
